| Small Lymphocytic Lymphoma
Calquence Tablets vs Jaypirca
Side-by-side clinical, coverage, and cost comparison for small lymphocytic lymphoma.Deep comparison between: Calquence vs Jaypirca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJaypirca has a higher rate of injection site reactions vs Calquence based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jaypirca but not Calquence, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Calquence
Jaypirca
At A Glance
Oral
Every 12 hours
BTK inhibitor
Oral
Once daily
BTK inhibitor
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Dosing
Mantle cell lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity; swallow tablet whole with or without food (monotherapy or in combination with bendamustine and rituximab).
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity (monotherapy, or in combination with obinutuzumab or venetoclax).
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Upper respiratory tract infection, diarrhea, headache, musculoskeletal pain.
Serious Serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury.
Postmarketing Ventricular arrhythmias, drug induced liver injury.
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Pharmacology
Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK); it and its active metabolite ACP-5862 form a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK enzymatic activity and downstream B-cell proliferation, trafficking, chemotaxis, and adhesion pathways required for B-cell malignancy growth.
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Calquence
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Calquence
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Humana
Calquence
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CalquenceView full Calquence profile
JaypircaView full Jaypirca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.